A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Luca Viganò,Shadya Sara Darwish,Lorenza Rimassa,Matteo Cimino,Carlo Carnaghi,Matteo Donadon,Fabio Procopio,Nicola Personeni,Daniele Del Fabbro,Armando Santoro,Guido Torzilli +10 more
TL;DR: Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival, and the risk for early disease progression after chemotherapy should be considered.
Journal ArticleDOI
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli,Armando Santoro,Robin Kate Kelley,Edward Gane,Valérie Paradis,Ann Cleverly,Claire Smith,Shawn T. Estrem,Michael Man,Shuaicheng Wang,Michael Lahn,Eric Raymond,Karim A. Benhadji,Sandrine Faivre +13 more
TL;DR: Both baseline levels and changes from baseline of circulating AFP and TGF-β1 function as prognostic indicators of survival in second-line patients with advanced HCC.
Journal ArticleDOI
1295pefficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (alk)-rearranged (alk+) non-small cell lung cancer (nsclc): an update of ascend-1
Enriqueta Felip,Dong Wook Kim,Ranee Mehra,D.S.W. Tan,Laura Q.M. Chow,D.R. Camidge,Johan Vansteenkiste,Sunil Sharma,T. De Pas,G. J. Riely,Ben Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,G. Lui,Armando Santoro,Margarida Geraldes,Anthony Boral,A. Yovine,Alice T. Shaw +19 more
TL;DR: Ceritinib 750 mg/day shows potent anti-tumor activity in ALK+ NSCLC pts regardless of prior ALKi treatment status, and Discontinuation due to toxicity was uncommon.
Journal ArticleDOI
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
Matteo Simonelli,Pasquale Persico,Matteo Perrino,Paolo Andrea Zucali,Pierina Navarria,Federico Pessina,Marta Scorsetti,Lorenzo Bello,Armando Santoro +8 more
TL;DR: The role of predictive biomarkers of responsiveness to checkpoint blockade in the context of gliomas is explored, along with the development of combinatorial and potentially synergistic approaches with other established anti-cancer treatments or complementary immunotherapeutic modalities.
Journal ArticleDOI
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
Pietro Carotenuto,Somaieh Hedayat,Matteo Fassan,Vincenzo Cardinale,Andrea Lampis,Vincenza Guzzardo,Caterina Vicentini,Aldo Scarpa,Luciano Cascione,Daniele Costantini,Guido Carpino,Domenico Alvaro,Michele Ghidini,Francesco Trevisani,Robert te Poele,Massimiliano Salati,Sofia Ventura,Georgios Vlachogiannis,Jens C. Hahne,Luke Boulter,Stuart J. Forbes,Rachel V. Guest,Umberto Cillo,Ian Said-Huntingford,Ruwaida Begum,Elizabeth C Smyth,Vasiliki Michalarea,David Cunningham,Lorenza Rimassa,Armando Santoro,Massimo Roncalli,Vladimir Kirkin,Paul A. Clarke,Paul Workman,Nicola Valeri,Nicola Valeri,Chiara Braconi,Chiara Braconi,Chiara Braconi +38 more
TL;DR: Changes in single microRNA (miRNA) expression have been associated with chemo‐resistance in biliary tract cancers (BTCs), but a global assessment of the dynamic role of the microRNome has never been performed.